Real-World Utilization and Outcomes of Pre-Prescribed Emergency Medication Kits: A Paradigm Shift in Direct-to-Consumer Medical Preparedness (2026)
|
Quick Answer A 2026 real-world survey of 506 verified purchasers of The Wellness Company's eight-medication Medical Emergency Kit found that 71.9% used the kit at least once, 81.6% reported meaningful improvement within three days of use, and 95.8% reported some form of net benefit. Only 2.4% reported side effects, all mild. The study is a preprint posted on Zenodo — not yet peer-reviewed — built entirely on self-reported data with no control group, and all 11 authors are affiliated with or compensated by the company selling the kit. It should be read as hypothesis-generating, not proof of clinical effectiveness. |
Key Takeaways
- The first real-world data on pre-prescribed emergency medication kits comes from a 506-respondent survey, posted as a Zenodo preprint on June 23, 2026 — it has not been peer-reviewed.
- 71.9% of purchasers used their kit at least once; 28.3% used it three or more times.
- Respiratory illness was the leading reason for use (59.4% of episodes), followed by urinary, gastrointestinal, dental, and skin/soft-tissue concerns.
- 81.6% reported meaningful improvement within three days; overall self-reported net benefit was 95.8%.
- Only 2.4% reported any side effect, and all were mild; no severe events were reported.
- Preparedness benefits — peace of mind and feeling ready for a disruption — were reported even by people who never used the kit.
Introduction
Access to timely medical care remains uneven. Long wait times, physician shortages, pharmacy closures, travel-related barriers, and rising healthcare costs routinely delay treatment for common acute illnesses. Against that backdrop, direct-to-consumer companies now sell pre-prescribed "emergency medication kits" — collections of prescription drugs dispensed to a household before illness occurs, meant to sit in a cabinet until they're needed.
Until June 2026, no real-world utilization data existed for this product category. That changed with a preprint titled Real-World Utilization, Outcomes, and Safety of Pre-Prescribed Emergency Medication Kits, posted to the Zenodo research repository by a team affiliated with The Wellness Company (TWC) and the McCullough Foundation, with one co-author from Yale School of Public Health. This article reviews what the survey found, how the retailer has since packaged those findings for marketing purposes, and what a careful reader should and shouldn't take away from it.
About the Study and Its Authors
The paper — Real-World Utilization, Outcomes, and Safety of Pre-Prescribed Emergency Medication Kits — was posted to Zenodo on June 23, 2026 under a CC BY 4.0 license (DOI: 10.5281/zenodo.20817624). Zenodo is a general-purpose open research repository operated with CERN; it hosts preprints and datasets but does not itself conduct peer review. As of this writing, the paper has not been published in, or accepted by, a peer-reviewed medical journal.
The authorship list is:
- Nicolas Hulscher, MPH — McCullough Foundation; The Wellness Company
- James A. Thorp, MD — The Wellness Company
- Drew Pinsky, MD — The Wellness Company
- Peter Gillooly, MSc — The Wellness Company
- Foster Coulson — The Wellness Company
- Melissa Annazone — The Wellness Company
- Chloe Radesi — The Wellness Company
- Jessica Brooks — The Wellness Company
- Harvey Risch, MD, PhD — The Wellness Company; Yale School of Public Health
- Peter A. McCullough, MD, MPH — McCullough Foundation; The Wellness Company
- Kelly Victory, MD — The Wellness Company
Per the retailer's own published disclosure (reproduced in full in the Limitations section below), every author is affiliated with and/or receives salary support from The Wellness Company, and no external funding was received for the project.
What's Inside the Medical Emergency Kit
The kit evaluated in the study contains eight prescription medications, each dispensed following a telehealth consultation and review of medical history by a licensed U.S. provider:
| Medication | Drug Class | Strength / Quantity |
|---|---|---|
| Amoxicillin-clavulanate | β-lactam antibiotic | 875 mg · 28 tablets |
| Azithromycin | Macrolide antibiotic | 250 mg · 12 tablets |
| Doxycycline | Tetracycline antibiotic | 100 mg · 50 capsules |
| Trimethoprim-sulfamethoxazole | Sulfonamide antibiotic | 800/160 mg · 28 tablets |
| Metronidazole | Antibiotic / antiprotozoal | 500 mg · 30 tablets |
| Ivermectin | Antiparasitic | 12 mg · 25 capsules |
| Fluconazole | Azole antifungal | 150 mg · 2 tablets |
| Ondansetron | Antiemetic | 4 mg tablets |
Kits are accompanied by a printed guidebook and telehealth consultation access; the seller offers replenishment eligibility for up to two years. See the Regulatory and Clinical Context section below for important notes on the approved uses of these drugs.
Study Design and Who Was Surveyed
Researchers invited 5,525 eligible customers who had purchased the kit to complete an online survey; 506 completed responses were analyzed, a response rate of roughly 9.2%. Respondents skewed older and urban:
| Characteristic | Result |
|---|---|
| Eligible customers invited | 5,525 |
| Completed responses analyzed | 506 (≈9.2% response rate) |
| Mean age | 65.1 years |
| Aged 60 or over | 77% |
| Resided in a metropolitan ZIP code | 75% |
Proportions in the study carry 95% Wilson confidence intervals, a statistically appropriate choice for proportions derived from survey data.
How Often Were Kits Opened and Used?
The findings suggest these kits were not simply stored away and forgotten.
| Metric | Result |
|---|---|
| Opened the kit | 96.4% (487 of 505 answering) |
| Read most of the guidebook | 69.4% |
| Used at least once | 71.9% (364 of 506) |
| Used three or more times | 28.3% (143) |
| Used while traveling or in a remote setting | 31.1% (114 of 367 use-reporting respondents) |
How Quickly Are Kits Used After Purchase?
Among respondents describing a specific use episode, the time between receiving the kit and that episode was distributed as follows:
| Time to First Reported Use | Share of Episodes |
|---|---|
| Within 1 month | 4.6% (17) |
| Within 3 months | 22.3% (82) |
| Within 6 months | 30.0% (110) |
| Within 1 year | 32.7% (120) |
| More than 1 year | 10.4% (38) |
This suggests most kits are used within the first year of purchase, consistent with the idea that they function as a standing preparedness resource rather than a one-time purchase for a specific trip or event.
What Conditions Were Most Commonly Treated?
Respiratory illness dominated reported use, consistent with the kit's antibiotic-heavy composition:
| Condition | Share of Episodes |
|---|---|
| Respiratory illness | 59.4% (218 of 367) |
| Urinary symptoms | 15.0% |
| Other / not sure | 7.4% |
| Gastrointestinal illness | 6.3% |
| Dental concern | 5.7% |
| Skin / soft-tissue | 4.1% |
Most episodes occurred at home, though roughly one in five occurred during travel or in a remote setting where conventional healthcare access may have been limited.
How Effective Were the Kits?
The most-cited finding is a high rate of self-reported symptom improvement among the 333 intended-use episodes (defined as the prescribed recipient taking the medication):
| Outcome | Result |
|---|---|
| Meaningful improvement within 24 hours | 36.7% |
| Meaningful improvement within 3 days | 81.6% (95% CI 77.1–85.4) |
| Overall self-reported net benefit | 95.8% (318 of 332; 95% CI 93.0–97.5) |
"Net benefit" was defined broadly as any positive perceived difference. Among respondents who reported a benefit, the type of benefit broke down as follows:
| Type of Perceived Benefit | Share Reporting |
|---|---|
| Reduced need for urgent care / ER | 51.8% (95% CI 46.4–57.1) |
| Reduced disruption to daily life | 34.6% |
| Helped manage symptoms until care was available | 9.3% |
While these figures point to high user satisfaction, they are self-reported rather than physician-confirmed, and there was no comparison group of similar patients who did not have kit access — so it isn't possible to say how much of the reported improvement reflects the medications versus the natural course of the illness.
Impact on Healthcare-Seeking Behavior
Among intended-use episodes, 86.1% of respondents (95% CI 82.0–89.4) reported that they did not seek in-person clinic, urgent care, or hospital care after using the kit, and 51.8% perceived a reduced need for urgent care or emergency department visits. Escalation to care within seven days occurred after 5.4% of episodes (20 of 368 use-reporting respondents). If these self-reported patterns hold up under more rigorous study designs, they could have implications for healthcare system load — but as the authors themselves note, this survey cannot establish that causally.
The Cost-Offset Scenario, Explained Carefully
The Wellness Company's own marketing page for this study presents a "$391–$438 saved per episode" figure, framed against the kit's $299.99 retail price. It's worth being precise about what this number is and isn't:
- It is described by the retailer itself as an "exploratory," "perception-based," and "illustrative" cost-offset scenario.
- It is modeled using national average estimated ER/urgent-care costs, applied only to the subset of episodes where a respondent perceived they avoided such a visit.
- It is not derived from actual billing records, insurance claims, or verified healthcare spending by study participants.
- It assumes the perceived avoidance of care was accurate and that the alternative visit would have cost the modeled amount — neither of which the study verified.
In short: this is a marketing illustration built on top of a self-reported perception, not an empirical cost-effectiveness finding. Readers evaluating the kit's value proposition should treat it accordingly, and the study's own authors call for genuine cost-effectiveness research as a next step (see Future Research Directions).
Safety Findings
| Safety Metric | Result |
|---|---|
| Any side effect reported | 2.4% (8 of 332 intended-use episodes) |
| Severity | All classified as mild |
| Required emergency medical care | 0% reported |
No serious adverse events were reported in the survey. It's important to note that a self-selected survey of purchasers who chose to respond is not a substitute for formal pharmacovigilance — rare or delayed adverse events, and any that led non-respondents to stop participating, would not necessarily be captured here.
Preparedness and Peace of Mind
One of the more interesting findings is that a meaningful share of the perceived value came simply from having the kit, independent of use:
- 80.2% of all respondents reported significantly improved peace of mind.
- 82.8% felt much better prepared for healthcare disruptions.
- 62.6% of respondents who never used the kit still reported substantial peace-of-mind benefit.
- 68.3% of never-users still felt significantly more prepared.
This points to an "insurance-like" psychological benefit that exists independently of whether the medications are ever taken — a benefit that is real to the respondent but, by definition, has nothing to do with clinical efficacy.
Regulatory and Clinical Context
A few points of clinical context are worth stating plainly, since they don't appear in the study's marketing materials:
- Ivermectin's FDA-approved indications are limited to specific parasitic infections (such as strongyloidiasis and onchocerciasis) and, in topical form, rosacea and head lice. It is not FDA-approved for treating respiratory or gastrointestinal infections — the conditions that accounted for the large majority of reported kit use in this study. U.S. and other regulators have previously cautioned against off-label ivermectin use for viral respiratory illness such as COVID-19.
- The kit bundles five different antibiotics (a β-lactam, a macrolide, a tetracycline, a sulfonamide, and an antiprotozoal/antibiotic) intended for self-selection at the time of illness, based on guidebook instructions rather than an in-person exam or point-of-care testing. Broad-spectrum antibiotic use outside direct clinical oversight raises standard antimicrobial stewardship considerations — including the risk of treating a viral illness with an antibiotic, delaying diagnosis of a more serious condition, or contributing to resistance — that apply to this product category generally, independent of this specific study.
- The manufacturer's own guidance states the kit is intended for situations where immediate medical attention is not accessible, not as a substitute for regular medical care, and that a licensed provider should be consulted before use. Red-flag symptoms — chest pain, difficulty breathing, signs of sepsis, high fever in infants, or a severe allergic reaction — warrant emergency evaluation regardless of what is in the cabinet.
Strengths of the Study
- The largest published real-world dataset in this emerging product category to date.
- A verified-purchaser population, reducing the risk of responses from non-users.
- Episode-level outcome reporting rather than only aggregate satisfaction scores.
- A dedicated safety assessment alongside effectiveness questions.
- Both rural and urban respondents, with metro/non-metro breakdowns.
- Use of Wilson confidence intervals, an appropriate statistical choice for the proportions reported.
It is, genuinely, the first study to offer any real-world utilization data for this product category — a legitimate and useful contribution, provided its limits are read alongside its findings.
Limitations and Conflicts of Interest
1. Preprint, Not Peer-Reviewed
The paper has been posted to a repository, not published in or accepted by a peer-reviewed journal. Independent expert review — which can catch methodological issues, alternative explanations, or overstated conclusions — has not yet occurred.
2. Self-Reported Outcomes
All diagnoses, symptom improvements, and avoided healthcare visits were reported by participants and were not independently verified against medical records.
3. No Control Group
Without a comparison group, it's impossible to determine how much of the reported improvement reflects the medications versus natural recovery from self-limiting illness.
4. Selection Bias
Purchasers satisfied with the product may have been more likely to respond to the survey than dissatisfied ones.
5. Low Response Rate
The response fraction was approximately 9.2%, leaving real uncertainty about the experience of the roughly 91% who didn't respond.
6. Conflicts of Interest
This is the limitation that most changes how the findings should be read. Per the retailer's own published disclosure: "All authors are affiliated with and/or receive salary support from The Wellness Company (TWC), which operates the telemedicine platform through which the emergency medical kits evaluated in this analysis were prescribed and dispensed. No external funding was received for this project." One co-author holds a Yale School of Public Health affiliation, but per that same disclosure is also affiliated with or compensated by TWC. This does not automatically invalidate the findings, but it is a first-party study of a first-party product with no independent replication — a combination that calls for real caution before treating the results as generalizable.
What This Means for Patients
The survey suggests pre-prescribed emergency medication kits may offer practical advantages in situations where immediate healthcare access is genuinely difficult. Potential beneficiaries, per the authors' own framing, may include:
- Frequent travelers to areas with limited medical infrastructure
- Rural residents facing long distances to the nearest clinic
- Older adults managing recurring acute conditions
- People in disaster-prone regions planning for disrupted access to care
Emergency medication kits should complement — not replace — professional medical care, and any use should follow the guidebook and telehealth guidance provided with the kit, not self-diagnosis alone.
Future Research Directions
The study's own authors call for exactly the kind of follow-up work that would address its current limitations:
- Prospective, randomized controlled trials in populations at risk for the illnesses covered by the kit
- Medical-record validation of self-reported outcomes
- Healthcare claims analysis to verify perceived reductions in ER/urgent-care use
- Genuine cost-effectiveness studies, as distinct from the illustrative marketing scenario discussed above
- Independent replication by investigators without a financial relationship to the manufacturer
Expert Review: Bottom Line
This preprint offers the first real-world look at how a pre-prescribed emergency medication kit is actually used outside a clinical setting. The topline numbers — high engagement, frequent use for common acute illness, rapid self-reported improvement, and a low rate of reported adverse effects — are genuinely notable for a product category that had no published utilization data before this.
At the same time, this is a non-peer-reviewed, self-reported, uncontrolled survey conducted entirely by authors affiliated with the company that sells the product, with a roughly 9% response rate. Those factors don't erase the findings, but they place a real ceiling on how much weight the findings can currently bear. This is best read as a hypothesis-generating pilot dataset — one that argues for the independent, controlled research the authors themselves say is needed — rather than as evidence that the kit reduces ER visits, saves money, or outperforms usual care.
Frequently Asked Questions
What is the Medical Emergency Kit study?
It is a cross-sectional online survey of 506 verified purchasers of an eight-medication, direct-to-consumer emergency medication kit sold by The Wellness Company. It reports how often the kit was opened and used, what conditions it was used for, self-reported outcomes, and safety signals. It was posted as a preprint on Zenodo on June 23, 2026 and has not undergone independent peer review.
Is this study peer-reviewed?
No. As of this writing it is a preprint hosted on Zenodo, a general-purpose research repository, not a peer-reviewed medical journal. Preprints have not been through independent expert review, so conclusions should be treated as preliminary.
What medications are in the kit that was studied?
Amoxicillin-clavulanate, azithromycin, doxycycline, trimethoprim-sulfamethoxazole, metronidazole, ivermectin, fluconazole, and ondansetron, each dispensed after a telehealth review by a licensed U.S. provider.
How many people used their kit, and for what conditions?
71.9% used the kit at least once, and 28.3% used it three or more times. Respiratory illness accounted for 59.4% of described episodes, followed by urinary symptoms (15.0%), other/uncertain conditions (7.4%), gastrointestinal illness (6.3%), dental concerns (5.7%), and skin/soft-tissue issues (4.1%).
How effective did users report the kit to be?
Among 333 intended-use episodes, 81.6% reported meaningful improvement within three days and 36.7% within 24 hours. Overall self-reported net benefit was 95.8%. These are self-reported perceptions, not clinician-confirmed outcomes, and there was no control group.
Were there safety concerns reported in the study?
Side effects were reported in 2.4% of intended-use episodes (8 of 332), all described as mild. No severe adverse events or cases requiring emergency care were reported in the survey — though a self-selected survey isn't a substitute for formal safety monitoring.
Does the study prove the kit prevents ER visits or saves money?
No. 86.1% of respondents perceived they avoided a clinic, urgent care, or hospital visit after use, but this is a self-reported perception, not a verified reduction in medical claims. The "$391–$438 saved" figure published on the retailer's site is an illustrative marketing scenario based on national average ER cost estimates, not empirical billing data from study participants.
Who conducted the study, and are there conflicts of interest?
Eleven authors affiliated with the McCullough Foundation, The Wellness Company, and Yale School of Public Health. TWC's own disclosure states that all authors are affiliated with and/or receive salary support from The Wellness Company, which sells the kit evaluated. No external funding was reported.
Who might consider an emergency medication kit?
The authors suggest frequent travelers, rural residents, older adults, and people in areas with unreliable healthcare access. This is a hypothesis based on survey responses, not a clinical recommendation — any decision should involve a licensed healthcare provider.
Does an emergency medication kit replace a doctor or emergency care?
No. The manufacturer's own guidance states the kit is intended for situations where immediate medical attention is not accessible, not as a substitute for regular medical care. Serious symptoms — chest pain, difficulty breathing, high fever in infants, signs of a severe allergic reaction — still require emergency evaluation.
Where to Get a Medical Emergency Kit
The Wellness Company Medical Emergency Kit The Wellness Company describes its kit as offering:
|
Affiliate Disclosure: OneDayMD / Immune Systems Advisor has an affiliate relationship with The Wellness Company and may receive compensation from purchases made through this link. This does not influence our editorial content, evidence-level framing, or reporting of study limitations above.
References
Hulscher N, Thorp JA, Pinsky D, Gillooly P, Coulson F, Annazone M, Radesi C, Brooks J, Risch H, McCullough PA, Victory K. Real-World Utilization, Outcomes, and Safety of Pre-Prescribed Emergency Medication Kits. Zenodo. Posted June 23, 2026. DOI: 10.5281/zenodo.20817624. [Preprint, not peer-reviewed]
The Wellness Company. Medical Emergency Kit Study. twc.health. Accessed July 2026.
Originally published June 24, 2026 | Updated July 8, 2026 with granular condition and outcome-type data, illustrative cost-scenario context, preprint-status clarification, and regulatory notes. This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting, stopping, or self-administering any prescription medication.
Comments
Post a Comment